325 related articles for article (PubMed ID: 29208671)
81. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Shirvani VN; Ouatu-Lascar R; Kaur BS; Omary MB; Triadafilopoulos G
Gastroenterology; 2000 Mar; 118(3):487-96. PubMed ID: 10702199
[TBL] [Abstract][Full Text] [Related]
82. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
Streppel MM; Pai S; Campbell NR; Hu C; Yabuuchi S; Canto MI; Wang JS; Montgomery EA; Maitra A
Clin Cancer Res; 2013 Aug; 19(15):4067-78. PubMed ID: 23757351
[TBL] [Abstract][Full Text] [Related]
83. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
[TBL] [Abstract][Full Text] [Related]
84. [Endoscopic diagnosis of Barrett's adenocarcinoma].
Yoshio H; Takashi Y; Mitsuyo H; Nobuhiko Y; Tatsurou T; Kazuhiko S; Yoko H; Shigemasa I; Hisanaga M; Osamu H; Katsuyoshi S; Seishi U; Matsushita H; Masahiko T
Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):244-8. PubMed ID: 10379534
[TBL] [Abstract][Full Text] [Related]
85. Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.
Fang Y; Chen X; Bajpai M; Verma A; Das KM; Souza RF; Garman KS; Donohoe CL; O'Farrell NJ; Reynolds JV; Dvorak K
Ann N Y Acad Sci; 2013 Oct; 1300():187-199. PubMed ID: 24117642
[TBL] [Abstract][Full Text] [Related]
86. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
87. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
88. Low frequency electrical bioimpedance for the detection of inflammation and dysplasia in Barrett's oesophagus.
Gonzalez-Correa CA; Brown BH; Smallwood RH; Stephenson TJ; Stoddard CJ; Bardhan KD
Physiol Meas; 2003 May; 24(2):291-6. PubMed ID: 12812415
[TBL] [Abstract][Full Text] [Related]
89. [Relationship of the sialomucins (Tn and Stn antigens) with adenocarcinoma in Barrett's esophagus].
de Faria PC; Andreollo NA; Trevisan MA; Lopes LR
Rev Assoc Med Bras (1992); 2007; 53(4):360-4. PubMed ID: 17823742
[TBL] [Abstract][Full Text] [Related]
90. Nitric oxide-mediated invasion in Barrett's high-grade dysplasia and adenocarcinoma.
Clemons NJ; Shannon NB; Abeyratne LR; Walker CE; Saadi A; O'Donovan ML; Lao-Sirieix PP; Fitzgerald RC
Carcinogenesis; 2010 Sep; 31(9):1669-75. PubMed ID: 20584750
[TBL] [Abstract][Full Text] [Related]
91. Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker.
Sahm V; Maurer C; Baumeister T; Anand A; Strangmann J; Schmid RM; Wang TC; Quante M
Oncotarget; 2022; 13():347-359. PubMed ID: 35178191
[TBL] [Abstract][Full Text] [Related]
92. Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression.
Brun R; Naroditsky I; Waterman M; Ben-Izhak O; Groisman G; Ilan N; Vlodavsky I
Mod Pathol; 2009 Dec; 22(12):1548-54. PubMed ID: 19749739
[TBL] [Abstract][Full Text] [Related]
93. Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.
Ergun P; Kipcak S; Bor S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175524
[TBL] [Abstract][Full Text] [Related]
94. 1,25-dihydroxyvitamin D in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
Trowbridge R; Kizer RT; Mittal SK; Agrawal DK
Expert Rev Clin Immunol; 2013 Jun; 9(6):517-33. PubMed ID: 23730883
[TBL] [Abstract][Full Text] [Related]
95. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
Campos VJ; Mazzini GS; Juchem JF; Gurski RR
J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
[TBL] [Abstract][Full Text] [Related]
96. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.
Becker L; Huang Q; Mashimo H
Dis Esophagus; 2010 Feb; 23(2):168-74. PubMed ID: 19549212
[TBL] [Abstract][Full Text] [Related]
97. Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.
Schellnegger R; Quante A; Rospleszcz S; Schernhammer M; Höhl B; Tobiasch M; Pastula A; Brandtner A; Abrams JA; Strauch K; Schmid RM; Vieth M; Wang TC; Quante M
Cancer Prev Res (Phila); 2017 Jan; 10(1):55-66. PubMed ID: 27807078
[TBL] [Abstract][Full Text] [Related]
98. Host factors influence Barrett's carcinogenesis: findings from a mouse gastroduodenal reflux model.
Kanai S; Mukaisho KI; Yoshida S; Taniura N; Sugihara H
Esophagus; 2019 Jul; 16(3):264-271. PubMed ID: 30790117
[TBL] [Abstract][Full Text] [Related]
99. Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype.
Porter RJ; Murray GI; Brice DP; Petty RD; McLean MH
Br J Cancer; 2020 Feb; 122(4):545-554. PubMed ID: 31831860
[TBL] [Abstract][Full Text] [Related]
100. Barrett's esophagus: progression to adenocarcinoma and markers.
Fang D; Das KM; Cao W; Malhotra U; Triadafilopoulos G; Najarian RM; Hardie LJ; Lightdale CJ; Beales IL; Felix VN; Schneider PM; Bellizzi AM
Ann N Y Acad Sci; 2011 Sep; 1232():210-29. PubMed ID: 21950815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
